ABSTRACT

The updated German S3 guidelines "Colorectal Carcinoma" were created as part of the oncology program of the Association of the Scientific Medical Societies (AWMF), German Cancer Society and the German Cancer Aid under the auspices of the German Society for Digestive and Metabolic Disorders (DGVS) and they replace the previous guidelines from 2013. The main changes in the updated guidelines include the latest recommendations regarding endoscopy and adjuvant/neoadjuvant therapies as well as a complete restructuring of the section regarding therapeutic approach in metastases and in the palliative situation. The present manuscript discusses the importance of the current recommendations for radiological diagnosis and treatment and is intended to enhance the quality of patient information and patient care by widespread distribution.

Key Points:
- Radiological recommendations for treating patients with colorectal carcinoma are presented.
- The different possibilities of radiological imaging for diagnosis are documented in detail.
- Radiologists should be acquainted with the different possibilities of oncological intervention in patients with colorectal carcinoma.

Citation Format
Vogl TJ, Pereira PL, Schreyer AG et al. Updated S3 Guidelines – Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention. Fortschr Röntgenstr 2018; DOI 10.1055/a-0721-1947

ZUSAMMENFASSUNG

Introduction

An increasing rate of colorectal cancer has been seen over the last 30 years in industrialized countries. Therefore, with 64,000 new cases and approximately 26,000 deaths per year, colorectal carcinoma is one of the most common malignant tumors in Germany. However, both numbers are slight lower compared to 2013 (76,000 and 27,000, respectively). The lifetime incidence remains high (approx. 6%). Men are affected slightly more often than women, primarily in rectal carcinoma with a gender ratio of 6:4.

As in many tumor entities, the prognosis depends on the disease stage and has an average 5-year survival rate of 40–60%. As a result of the continuous further development of diagnostic methods and optimization of surgical, neoadjuvant and palliative treatment concepts, age-standardized mortality rates have decreased in the last 10 years by more than 20 percent.

This article discusses the relevant recommendations of the updated 2017 S3 guidelines for the radiological diagnosis and treatment of colorectal cancer with the main statements and corresponding literature.

Method

The guidelines were coordinated and planned under the auspices of the German Society for Digestive and Metabolic Disorders, which was supported by the oncology guidelines program of the Association of the Scientific Medical Societies. This program is based on the medical knowledge of the professional societies and the German Cancer Society, the consensus of medical experts, users and patients and the rules for guideline creation of the Association of the Scientific Medical Societies. The use of the rules of the Association of the Scientific Medical Societies should serve as the basis for the development of high-quality oncology guidelines. The method is explicitly described in the guidelines report.

The levels of evidence of the systematically researched data were assigned according to the system of the Oxford Centre for Evidence-based Medicine (Table 1) from which grades of recommendation for clinical assessment were derived (Fig. 1).

A group of experts with a total of 53 elected representatives and plenum members from 14 German medical societies and 7 additional professional organizations and associations were involved in the revision of the guidelines. They met twice for consensus building and discussions. The strength of consensus was classified based on the approval rating of the plenum (Table 2).

The long version of these guidelines was published in the German Journal of Gastroenterology and is published online on the homepages of the oncology guidelines program of the German Cancer Society (www.leitlinienprogramm-onkologie.de), the Association of the Scientific Medical Societies (www.awmf.org), the German Cancer Aid (www.krebshilfe.de) and the German Society for Digestive and Metabolic Disorders (www.dgvs.de). In addition to the long version, a short version, a guidelines report, and evidence reports are published here.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Levels of evidence according to Oxford.</th>
</tr>
</thead>
<tbody>
<tr>
<td>grade</td>
<td>type of study</td>
</tr>
<tr>
<td>1a</td>
<td>systematic overview of randomized controlled studies (RCT)</td>
</tr>
<tr>
<td>1b</td>
<td>RCT (with narrow confidence interval)</td>
</tr>
<tr>
<td>1c</td>
<td>all-or-none principle</td>
</tr>
<tr>
<td>2a</td>
<td>systematic overview of well-designed cohort studies</td>
</tr>
<tr>
<td>2b</td>
<td>A well-designed cohort study or an RCT of lower quality</td>
</tr>
<tr>
<td>2c</td>
<td>outcome studies, ecological studies</td>
</tr>
<tr>
<td>3a</td>
<td>systematic overview of case control studies</td>
</tr>
<tr>
<td>3b</td>
<td>one case control study</td>
</tr>
<tr>
<td>4</td>
<td>case series or cohort/case control studies of lower quality</td>
</tr>
<tr>
<td>5</td>
<td>expert opinion without explicit evaluation of the evidence or based on physiological models/laboratory research</td>
</tr>
</tbody>
</table>

Primary diagnosis

Since it has the highest sensitivity and specificity in the early detection of colorectal neoplasias, colonoscopy continues to be the gold standard both in preventive care (screening) and in preoperative diagnosis. Since endoscopic methods also offer the advantage of therapeutic ablation, the adenoma-carcinoma sequence can be interrupted by endoscopic ablation and the formation of carcinomas and the colorectal cancer-based mortality can be consequently reduced [1]. Since synchronous tumors that can be missed by intraoperative assessment can be expected in up to 5% of colorectal carcinomas, colonoscopy of the entire colon should generally be performed [1–4].
CT or MR colonography

**CONSENSUS-BASED STATEMENT**
CT colonography and MR colonography should not be used for colon cancer prevention/early detection in asymptomatic patients.

*Level of evidence 3b – De Novo*
*Grade of recommendation B*
*Vote in the plenum: Strong consensus*

**Comment**
Even though the American Cancer Society has recommended CT colonography as a screening alternative in colorectal carcinoma since April 2008 [5], this is still not permitted in asymptomatic patients in Germany due to the radiation exposure and high availability of alternative endoscopic methods (Radiation Protection Ordinance § 80). MR colonography is also currently not allowed as a screening method due to an insufficient number of studies [6, 7].

**CONSENSUS-BASED RECOMMENDATION**
In the case of incomplete colonoscopy due to a tumor causing stenosis, CT or MR colonography can additionally be performed on a preoperative basis.

*Grade of recommendation 0*
*Level of evidence 4*
*Vote in the plenum: Strong consensus*

In the case of incomplete colonoscopy for other reasons (e.g., adhesions), CT or MR colonography should be performed.

*Grade of recommendation B*
*Level of evidence 4*
*Vote in the plenum: Strong consensus*

**Comment**
However, if colonoscopy cannot be performed for technical reasons or due to patient refusal, both CT colonography [8, 9] and, to a lesser degree, MR colonography can be used as alternative radiological methods [10]. At least with respect to computed tomography (CT), this recommendation is in accordance with the joint guidelines of the European Society for Gastrointestinal Endoscopy and the European Society of Gastrointestinal and Abdominal Radiology from 2014 [11]. Two current meta-analyses show a sensitivity of 100 % for the detection of carcinomas and 87.9 % for the detection of adenomas ≥ 10 mm. In the case of adenomas > 5 mm, the sensitivity and specificity of CT colonography in screening candidates with a positive stool test decreased to 88 % and 75 %, respectively [11]. In particular, flat polyps still often cannot be adequately detected [12 – 15].

In addition to a lack of expertise, suboptimal patient preparation and inadequate examination procedures limit the ability to obtain a valid interpretation of virtual colonography. Consequently, standardized training is needed in order to achieve knowledge of examination and evaluation techniques. Therefore, the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) as well as the American College of Radiology recommend performing at least 50 CT colonography examinations as part of training programs.

The primary goal of virtual colonography is thus to rule out additional lesions suspicious for malignancy so that it falls under the staging domains discussed in the following.

**Staging**

**Importance of individual imaging methods (except PET) for diagnosing distant metastases**

**CONSENSUS-BASED STATEMENT**
Abdominal ultrasound and conventional chest X-ray on 2 levels should be performed as basic examinations for the preoperative staging of colorectal cancer. Multi-slice CT of the abdomen and pelvis should be performed in the case of an unclear finding or suspicion of distant metastases or infiltration of neighboring organs or surrounding structures and chest CT in the case of the suspicion of lung metastases.

*Grade of recommendation: GCP*
*Vote in the plenum: Consensus*

**Comment**
Pretherapeutic imaging is primarily used to assess distant metastases and lymphadenopathy. In 25 % of patients with colon cancer and 18 % of patients with rectal cancer, distant metastases are already present at the time of initial diagnosis. Metastases of colon cancer are restricted to one organ (M1a) in 13 % of cases and to more than one organ or to the peritoneum (M1b) in 12 % of cases. Liver metastases are seen in 19 % of cases, lung metastases in 3 %, and peritoneal metastases in 9 %. Additional distant metastases in non-regional lymph nodes (2 %), the skin (2 %), the ovary (1 %), bone (< 1 %), or other locations (2 %) are rare. Metastases of rectal cancer are restricted to one organ (M1a) in 12 % of cases and to more than one organ or to the peritoneum (M1b) 6 % of cases. Distant metastases in the liver are seen in 15 % of cases.

---

**Table 2 Classification of strength of consensus.**

<table>
<thead>
<tr>
<th>strength of consensus</th>
<th>agreement in percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>strong consensus</td>
<td>agreement of &gt; 95 % of participants</td>
</tr>
<tr>
<td>consensus</td>
<td>agreement &gt; 75 – 95 % of participants</td>
</tr>
<tr>
<td>majority agreement</td>
<td>agreement &gt; 50 – 75 % of participants</td>
</tr>
<tr>
<td>no consensus</td>
<td>agreement of less than 50 % of participants</td>
</tr>
</tbody>
</table>
and lung metastases in 4%. Additional distant metastases are seen in the peritoneum in 3% of cases and in non-regional lymph nodes in 2% of cases. Distant metastases in the skin, bone, brain, ovary, or other locations are seen in fewer than 1% of cases. [Data from the Clinical Cancer Registry of the Surgical Clinic of the University of Erlangen-Nuremberg].

Primary conventional chest X-ray is sufficient for detecting lung metastases – concordant with simultaneous hepatic metastases in 45–70% of cases [16, 17]. Compared to conventional imaging, chest CT shows higher sensitivity for the detection of pulmonary masses but significantly lower specificity. Based on the currently available studies, the clinical benefit of preoperative chest CT has not been sufficiently verified [17].

To diagnose liver metastases, primary abdominal ultrasound should be performed (sensitivity 63–86%, specificity 98%) [18–20]. Contrast-enhanced ultrasound of the liver is almost equivalent (sensitivity 83–86%, specificity 94–98%) to CT and MRI but requires adequate quality standards (technical equipment and examiner experience) [19, 20]. Therefore, abdominal CT examination (sensitivity 75–83%, specificity 95–98%) should be additionally performed in the case of suspicious ultrasound findings, insufficient ability to assess the liver on ultrasound or clinical suspicion of liver metastases [18, 21]. This allows assessment not only of the segmental allocation but also of the vascular supply and thus resectability of metastases. Alternatively, MRI of the liver whose diagnostic accuracy is superior to that of CT (sensitivity and specificity: MRI 80–88% and 93–97%, CT 74–84%, and 95–96%) can also be performed [18, 21]. Since abdominal CT examination also allows assessment of the local tumor size, there is a tendency to perform primary abdominal CT examination instead of or in addition to ultrasound. However, in studies in patients with colon cancer, the routine use of preoperative CT resulted in a change in the further approach in only a few cases [22, 23].

Value of CT and MRI in preoperative local staging

CONSENSUS-BASED RECOMMENDATION

CT examination for preoperative staging can be used to differentiate between tumors that are limited to the intestinal wall and those that extend beyond it. However, the identification of nodal status is significantly more difficult. Multi-slice CT (MSCT) provides the best results.

Grade of recommendation: GCP

Vote in the plenum: Consensus

Comment

Preoperative ultrasound examination of the abdomen is insufficient for selection of the treatment algorithm. Multi-slice CT (MSCT) achieves high sensitivity (86%) and specificity (78%) for the evaluation of local tumor infiltration. However, local lymph node metastases are detected with a significantly lower sensitivity (70%) [24]. There is currently insufficient data regarding the accuracy of MRI images for the local staging of colon cancer.

Value of PET-CT in the primary diagnosis of colorectal cancer

CONSENSUS-BASED STATEMENT

PET/PET-CT is not useful for staging in the initial diagnosis of colorectal cancer.

Level of evidence 2b – De Novo

Vote in the plenum: Strong consensus

Comment

There are multiple comparative studies regarding the sensitivity of PET for distant metastases with overall heterogeneous study data [24, 25]. Newer comparison studies using a multidetector spiral CT unit show no significant benefit of PET [26, 27].

Due to the low resolution of PET, the sensitivity for lymph node metastases is also low (29–85%). Therefore, the method is not superior to other imaging modalities. Accordingly, the use of PET and PET-CT resulted in a change in the therapeutic approach in only 2–27% of cases [26–29].

CONSENSUS-BASED RECOMMENDATION

PET-CT can be performed in patients with resectable liver metastases of colorectal carcinoma with the goal of avoiding an unnecessary laparotomy.

Grade of recommendation 0

Level of evidence 2b – De Novo

Vote in the plenum: Consensus

Comment

Supplementary PET/PET-CT examination does not affect the disease-free or overall survival of colorectal cancer patients [30]. The study that served as the basis for the grade of recommendation B for the implementation of PET/PET-CT prior to resection of colorectal liver metastases in the last update of the guidelines in 2008 has not yet been published as a manuscript [31]. Therefore, the grade of recommendation has been downgraded in the current guidelines.

The question as to whether supplementary PET-CT scan can prevent unnecessary laparotomies as a clinically relevant end point has not yet been definitively clarified by the currently available studies: However, one study including 150 patients with hepatic metastases of colorectal cancer was able to show that the percentage of unnecessary laparotomies was able to be lowered from 45% to 28% by performing a supplementary PET scan [32].

A supplementary PET/PET-CT scan prior to resection of liver metastases of colorectal cancer has no effect on the disease-free or overall survival of patients. The question as to whether a supplementary PET-CT examination can prevent unnecessary laparotomies as a clinically relevant end point has not yet been definitively clarified. The consensus recommendation is based on only one published study [32] albeit with methodological flaws. There was no significant difference in the survival rate in the PET-
arm but there was a significant reduction in the number of unness-
cessary laparotomies of 38 % with a large confidence interval
(95 % CI, 4 – 60 %, p = 0.042). The level of evidence of the study
was downgraded by the consensus conference since the primary
study end point indicated in the study plan deviated from that
stated in the publication (original end point: rate of patients who
were disease-free after 9 months). A further multicenter random-
ized study presented as an abstract at the ASCO annual meeting in
2011 also examined this issue [33]. The end point of this study
was a change in patient management following PET imaging but
was not achieved due to a lack of change.

**CONSENSUS-BASED RECOMMENDATION**
PET-CT should not be performed within 4 weeks after the
administration of systemic chemotherapy or antibody therapy
since the sensitivity is significantly reduced.
*Grade of recommendation: A*
*Level of evidence: 2b – De Novo*
*Vote in the plenum: Strong consensus*

**Comment**
Due to an excessive number of false-negative PET findings
within 4 weeks of systemic chemotherapy or antibody therapy,
PET cannot be recommended within this time period [34, 35].

**Special diagnostic methods in the case of rectal
cancer**

**CONSENSUS-BASED STATEMENT**
MRI should preferably be performed for the local staging
of rectal cancer, while endoscopic ultrasound should be
performed in suspected T1 carcinoma.
*Grade of recommendation: B*
*Level of evidence: 2b – De Novo*
*Vote in the plenum: Strong consensus*

**CONSENSUS-BASED STATEMENT**
CT is not suitable for T1 carcinomas.
*Level of evidence: 3 – De Novo*
*Vote in the plenum: Strong consensus*

**CONSENSUS-BASED STATEMENT**
The report should include a statement regarding the distance
from mesorectal fascia.
*Grade of recommendation: GCP*
*Vote in the plenum: Strong consensus*

**Comment**
In light of the ability to visualize the mesorectal fascia in partic-
ular, MRI is currently preferred by many experts for the local stag-
ing of rectal cancer, with the exception of early carcinomas.

Local staging is particularly important for further treatment
planning in the case of rectal cancer. While local ablation is suffi-
cient for a low-risk T1 carcinoma, resection according to oncologi-
cal criteria is necessary in high-risk T1 and T2 carcinomas.

Endoscopic ultrasound (EUS) has the highest accuracy in the
diagnosis of T1 carcinomas and the differentiation of T2 and
T3 carcinomas [36, 37]. MRI using an endorectal coil is a possible
alternative to EUS but is associated with higher costs, is unplea-
sant for patients, and is established at only a few locations. CT is
not suitable for this purpose.

Deeper rectal infiltrations with infiltration into the mesorec-
tum (T3 and T4) required neoadjuvant therapy so that the
distance from the mesorectal fascia has important prognostic
significance [38]. If the mesorectal fascia has been infiltrated or if
the tumor is within 1 mm of the fascia (CRM+), the local recur-
rence risk is significantly higher [38].

Since the mesorectal fascia can be effectively visualized on MRI
in contrast to endoscopic ultrasound, MRI should be preferably
used for the local staging of rectal cancer [6]. Spiral CT is a pos-
sible alternative [39]. The fascia cannot be visualized with endo-
scopic ultrasound.

**CONSENSUS-BASED STATEMENT**
The radial distance of the primary tumor (or affected lymph
nodes) from the mesorectal fascia measured on thin-slice
MRI (mrCRM) should not be used as a decision criterion for
primary surgery outside of studies.
*Grade of recommendation: GCP*
*Vote in the plenum: Consensus*

**Comment**
The mrCRM determined by thin-slice MRI has a high prognostic
significance for local control and disease-free survival and overall
survival [31]. However, subgroup analyses of large randomized
studies show that preoperative radiotherapy resulted in a further
significant improvement in the local recurrence rate particularly
in the case of pCRM-negative resection [40]. Therefore, the determi-
nation of the indication for neoadjuvant radiotherapy/radioche-
motherapy versus primary surgery solely in relation to the selec-
tion criterion mrCRM currently requires additional quality-
assured, prospective studies.

**CONSENSUS-BASED STATEMENT**
All imaging methods are subject to significant diagnostic
uncertainty in the evaluation of lymph node status.
*Level of evidence: 2b – De Novo*
*Vote in the plenum: Strong consensus*
Comment
The sensitivity (55 – 73 %) and specificity (74 – 78 %) of all methods in the evaluation of lymph nodes are currently unsatisfactory [37]. For this reason, the indication for neoadjuvant therapy should be made in a very conservative manner when it is based solely on the description of suspicious lymph nodes on pretherapeutic imaging. ▶ Table 3 shows an overview of preoperative staging.

Treatment-relevant recommendations
Interdisciplinary tumor conference

CONSENSUS-BASED STATEMENT
All patients with colorectal cancer should be presented in an interdisciplinary tumor conference after the completion of primary therapy (e.g. surgery, chemotherapy). Patients should be presented on a pretherapeutic basis in the following constellations:
- All cases of rectal cancer
- All cases of stage IV colon cancer
- Metachronous distant metastases
- Local recurrence
- Prior to every local ablation or locoregional measure, e.g. RFA/LITT/SIRT

Grade of recommendation: GCP
Vote in the plenum: Consensus

Local ablation methods

CONSENSUS-BASED RECOMMENDATION
Local ablation methods can be used in the case of non-resectable metastases or if the general condition of the patient does not allow resection, particularly after previous liver metastasis resection.

Level of evidence 3b
Vote in the plenum: Strong consensus

Comment
Due to the complexity of the treatment of colorectal carcinoma, the treatment concept should be discussed in an interdisciplinary tumor conference consisting of an experienced visceral surgeon, and at least one representative from the fields of gastroenterology, oncology, radiation therapy, radiology, and pathology.

The basic treatment goal in the case of colorectal carcinoma is radical surgical removal provided that a curative concept is possible.

In the case of distant metastases, primary or secondary resection of the metastases should be evaluated. Due to the intestinal blood flow through the portal vein and the right heart system, hepatic and pulmonary metastases are primarily seen here.

If R0 resection seems possible, primary surgery should be targeted. The 5-year survival rate after complete resection of colorectal liver metastases is between 25 % and 40 %.

If a surgical approach is not possible, local ablation can also be used with a curative treatment intent.
Local ablation methods for treating liver metastases

Thermoablation

There is sufficient data regarding the safety and efficacy of radiofrequency ablation (RFA) for the treatment of hepatic metastases supporting its use in patients who have non-resectable liver metastases, whose condition does not allow resection or who previously underwent liver resection [44]. RFA and MWA are to be considered largely equivalent here. However, MWA compared to RFA seems to be associated with a low local recurrence rate in the treatment of colorectal liver metastases close to large vessels [45].

The long-term survival of patients of up to 10 years after thermoablation is well documented in oligometastases to the liver [46]. Cohort studies and retrospective analyses show no difference between resection and thermoablation in metastases with a diameter of up to 3 – 4 cm with respect to survival [47 – 49] so that thermoablation can be offered as an alternative to resection in the corresponding clinical constellation. However, a safety distance between the metastasis and induced coagulation of 5 mm should be maintained [50]. Multiple studies highlight the advantages of ablation with the possibility of repeating the intervention.

The combination of RFA (plus surgical) treatment and chemotherapy seems to result in a significant increase in the PFS as well as the overall survival [32].

Even if LITT is also an efficient and safe method for local ablation of inoperable liver metastases [51, 52], LITT and electroporation currently cannot be recommended for the treatment of liver metastases in colorectal cancer outside of clinical studies given the continued lack of prospective controlled studies.

Additional locally effective interventions

To date, the use of other local ablation methods has been primarily examined in case series and small cohort studies so that their oncological value has not yet been sufficiently validated [53, 54]. This includes methods with insufficient evidence such as stereotactic radiation (SBRT), brachytherapy, cryotherapy, and irreversible electroporation (IRE).

A 2-year survival rate between 32 % and 83 % for SBRT is specified in the literature [55, 56], and a median survival rate of up to 23.4 months for brachytherapy [57]. Studies including larger patient populations with a 5-year survival rate or randomized studies compared to surgical resection or thermoablation for colorectal liver metastases are currently not available.

Local ablation methods for treating lung metastases

The resectability of lung metastases and local treatment with the option of ablation (RFA, MWA) or radiation therapy (SBRT) should be decided by a multidisciplinary tumor board. Therefore, depending on the technique, local control between 69.2 % and 88.3 % seems to be possible given the presence of a maximum of 3 lung metastases with a maximum size of 3 cm per lung [58, 59]. However, randomized studies are currently not available. There are also no randomized studies regarding SBRT of lung metastases with only small published case numbers with risks of radiation-induced pneumonitis and restriction of the functional lung volume.

Locoregional methods

Locoregional methods include selective intraarterial radiotherapy (SIRT) and intraarterial chemotherapy of the liver (HAI, TACE).

Selective intraarterial radioembolization (SIRT)

**CONSENSUS-BASED RECOMMENDATION**

SIRT can be used to treat disseminated liver metastases in colorectal cancer in patients for whom no other equivalent treatment option is possible.

*Level of evidence 2b*

*Vote in the plenum: Strong consensus*

**Comment**

In comparatively small randomized studies, the combination of SIRT with 5-FU was more effective than chemotherapy alone. Both in “chemorefractory” patients treated multiple times and in first-line therapy, the inclusion of SIRT compared to treatment solely with 5-FU resulted in an improvement in response rate (10 % versus 0 % for chemorefractory patients), TTP (4.5 vs. 2.1 months for chemorefractory patients or 18.6 versus 3.6 months, p < 0.0005 in first-line therapy) and OS (29.4 vs. 12.8 months, p = 0.025 in first-line therapy) [60, 61].

In an analysis of 3 randomized multicenter studies, the combination of SIRT and oxaliplatin/5-FU-based first-line chemotherapy showed a significant improvement in response rate (odds ratio 1.52, p = 0.001) and potential resectability [62] but no advantage with respect to PFS and overall survival. The low effect on the overall survival can be partly explained by the high percentage of synchronous hepatic and extrahepatic metastases at the start of treatment [62].

Hepatic intraarterial chemotherapy (HAI)

A current European multicenter phase II study shows that resectability associated with a 4-year survival rate of 37.4 % can be achieved in second-line therapy with high-dose intraarterial chemotherapy. However, consensus regarding a recommendation for the implementation of HAI in liver-dominant metastases at specialized centers could not be reached.

Use of irinotecan-loaded microbeads

A prospective randomized study in the palliative situation in patients with disease progression after second- and third-line chemotherapy showed better survival with a better quality of life after intraarterial application of irinotecan-loaded particles [63]. A further prospective randomized study reported better response rates with better progression-free survival using a combination of FOLFOX+/-bevacizumab with irinotecan-loaded particles compared to FOLFOX administration+/-bevacizumab [64].
Follow-up

**CONSENSUS-BASED RECOMMENDATION**
Regular follow-up in patients with colorectal carcinoma and early tumor stage (UICC I) is not recommended after R0 resection in light of the low recurrence rate and the favorable prognosis. Follow-up colonoscopy should be performed in accordance with section 3.8.3 of the new S3 guidelines.

*Grade of recommendation: GCP*

**CONSENSUS-BASED STATEMENT**
Regular follow-up examinations are indicated after R0 resection of colorectal carcinomas of UICC stages II and III.

*Grade of recommendation A*
*Level of evidence 1a*
*Vote in the plenum: Strong consensus*

However, in the case of recurrence, these examinations should only be performed if therapeutic consequences are to be expected.

*Grade of recommendation: GCP*
*Vote in the plenum: Strong consensus*

**Comment**
The goal of follow-up is to detect a recurrence in a potentially curative stage. After curative therapy, there is an increased risk for local or locoregional recurrence (3 – 24 %), the occurrence of distant metastases (25 %), and a metachronous secondary tumor (1.5 – 10 %) for 5 years. The recurrence risk is increased particularly in advanced tumor stages [38, 65].

A prospective study showed that patients with a long-term survival of 86 % in UICC stage I have a very good prognosis after curative resection. The recurrence rate here was 4 % in UICC stage Ia and 13 % in UICC stage Ib, while a recurrence rate of 2.9 % in UICC stage Ia and a recurrence rate of only 5.6 % for UICC stage Ib were determined in a large retrospective study. The primary location of recurrence is the rectum (11 %) [66, 67].

Multiple meta-analyses showed heterogeneous study data regarding programmed follow-up in advanced colorectal cancer stages with a lower benefit tendency to be achieved by regular follow-ups. The general efficacy of colorectal cancer follow-up correlates with a survival time that is only 1 % longer on average [68].

Based on this and in light of the low recurrence rate, regular follow-up of R0-resected colorectal carcinomas in UICC stage I is not recommended.

If an increased recurrence rate is expected based on intraoperative or pathological findings, frequent follow-up colonoscopy examinations can be performed in the individual case.

In comparison, the recurrence rate in advanced colorectal cancer (UICC stages II + III) is increased [38, 69]. Regular follow-up examinations should be performed in this case. However, evidence-based statements regarding the type and frequency of follow-up examinations cannot be made due to a lack of studies [70]. More intensive follow-up did not yield a benefit compared to standard follow-up in the majority of randomized controlled studies [71, 72].

Only endoscopic ultrasound is recommended in the updated guidelines as the visual detection method for programmed follow-up. The methods specified in the following can be optionally performed.

**Value of diagnostic methods for follow-up**

**Ultrasound**

**CONSENSUS-BASED RECOMMENDATION**
Ultrasound is technically suitable for detecting liver metastases. Routine use has not been established based on the available data. The expert commission considers ultrasound to be the simplest and most cost-effective method and therefore recommends its use for diagnosing liver metastases.

*Grade of recommendation A*
*Level of evidence 5*
*Vote in the plenum: Strong consensus*

**Comment**
In a controlled randomized study [73], the use of ultrasound (and also computed tomography) did not affect the survival and resection rates of patients undergoing follow-up. Only one meta-analysis of multiple randomized studies showed a significant survival advantage from using an imaging method to evaluate the liver [74]. Although a lower sensitivity of ultrasound compared to CT was seen in most studies, abdominal ultrasound is recommended as a cost-effective, fast, and widely available method for detecting liver metastases.

In the case of rectal cancer, follow-up with endoscopic ultrasound is useful in the diagnosis of locoregional recurrence after sphincter-preserving rectal resection if endoscopic ultrasound is combined with biopsy [75]. However, due to the invasiveness of biopsy, endoscopic ultrasound should only be used when the suspicion of recurrence has already been raised by another examination modality.

**EUS**

**CONSENSUS-BASED RECOMMENDATION**
EUS is suitable for detecting local recurrence in the case of rectal cancer, particularly in combination with EUS-guided biopsy. A recommendation regarding routine primary use in follow-up currently cannot be made.

*Grade of recommendation B*
*Level of evidence 3b*
*Vote in the plenum: Strong consensus*
CONSENSUS-BASED RECOMMENDATION

A chest X-ray can be performed annually in patients with stage II and III rectal cancer to the fifth year.

Grade of recommendation 0
Level of evidence 3b – De Novo
Vote in the plenum: Consensus

Comment

The systematic literature research performed by the authors of the S3 guidelines regarding the significance of conventional chest X-ray showed that 0.8 % to 7.0 % of all colorectal cancer patients having undergone curative resection developed pulmonary metastases and that 3.4 to 29.4 % of all cases of pulmonary recurrence were detected by chest X-ray.

If a differentiation is made between colon and rectal carcinomas, the benefit of chest X-ray seems to be higher in rectal cancer in accordance with the more frequent rates of metastasis than in colon cancer [16]. The benefit for colon cancer is not definitive enough to be able to make a recommendation for routine use of chest X-ray in follow-up.

CONSENSUS-BASED STATEMENT

Contrast enema, virtual colonography and PET, PET-CT and PET-MRI are not useful for programmed follow-up.

Grade of recommendation B
Level of evidence 4 – De Novo
Vote in the plenum: Strong consensus

Comment

To date, there is no data regarding the use of contrast enemas and virtual colonography in the follow-up of colorectal cancer. Therefore, virtual colonography does not replace endoscopic ultrasound methods of follow-up.

Only a few studies address the use of PET imaging for the programmed follow-up of asymptomatic colorectal cancer patients. In a prospective randomized study published in 2003 by Winawer et al., a control group examined in the follow-up with conventional chest X-ray and abdominal ultrasound and CT was compared to a study group additionally examined with PET imaging. With the same recurrence rate, recurrences were detected an average of 3.2 months earlier in the PET group resulting in a greater number of surgical procedures [77]. Also in other studies with supposed absence of recurrence, recurrences were diagnosed earlier with PET imaging [78, 79]. However, a statement regarding the effect on the average survival time could not be made in the studies.

In light of the insufficient data available and the surgical consequences resulting in some cases from false-positive PET findings, the use of PET imaging for follow-up examination without a suspicion of recurrence is not currently recommended [77].

Summary

The new S3 guidelines on colorectal carcinoma replace the previous guidelines from 2013 and include updated recommendations regarding endoscopic ultrasound and adjuvant/neoadjuvant therapy primarily with complete revision and restructuring of the section regarding the therapeutic approach for metastases and in the palliative situation. The guidelines relate to a number of areas in radiology.

The recommendations regarding the value of radiology methods in preoperative diagnosis remain unchanged. Therefore, the recommendation is still to use CT or MR colonography only in the case of suspicion of malignancy and when endoscopic ultrasound is not technically feasible.

The fact that neither CT colonography – due to unnecessary radiation exposure – nor MR colonography – due to insufficient data – can currently be recommended for screening examinations in asymptomatic patients also remains unchanged.

Percutaneous abdominal ultrasound remains the method of choice for the locoregional staging of colorectal cancer. Only in the case of an unclear or pathological abdominal ultrasound find-
ing or suspicion of infiltration of neighboring organs or surrounding structures should abdominal CT be performed for further diagnostic workup.

Chest X-ray on two planes is sufficient for the primary diagnosis of lung metastases and chest CT should only be added in the case of clinical suspicion of pulmonary metastases. There is still insufficient data to be able to recommend unrestricted use of MRI imaging in the staging of colon cancer in the guidelines. However, MRI can be used to best determine the oncologically relevant infiltration depth in the direction of the mesorectal fascia so that the method should be used in the local staging of advanced rectal carcinomas (≥ stage T2).

PET is still not recommended for the primary staging of colorectal carcinoma. However, it can be used in the case of the presence of potentially resectable liver metastases to prevent unnecessary laparotomies. Therefore, the grade of recommendation for preoperative FDG-PET-CT remains 0.

The recommendations regarding the use of radiology methods for follow-up have also not changed. Conventional chest X-ray can be performed postoperatively in patients with stage II and III rectal cancer in the first five years.

The use of computed tomography for detecting recurrence and metastases continues to be recommended only in the case of clinical suspicion or suspicious laboratory results and should not be performed as part of systematic follow-up. Contrast enema, virtual colonography and PET, PET-CT and PET-MRI are still not recommended for programmed follow-up.

The new guidelines include extensive additions primarily regarding the therapeutic use of local ablation methods and also locoregional methods for the first time. The grade of recommendation for local ablation methods was increased from 3a to 3b and can thus be used if non-resectable metastases are present or the general condition of the patient does not allow resection, particularly after previous liver metastasis resection. However, this recommendation relates secondarily and exclusively to the thermoablation methods cryotherapy, SBRT, and brachytherapy have been included in the guidelines for the first time but are not recommended due to insufficient validation. SIRT as a locoregional method was upgraded from degree of recommendation 2a to 2b and can thus now also be used outside of studies for the treatment of disseminated colorectal liver metastases for which there is no other equivalent treatment option. No recommendation was made regarding HAI, TACE, and the locoregional application of irinotecan-loaded microbeads in liver-dominant metastases. This also relates to the local ablation of lung metastases via RFA, MWA, and SBRT. Nonetheless, all of these methods and indications have been included in the new guidelines for the first time.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


